Hematologists use Anti-thymocyte globulin (ATG) as a cornerstone therapy to prevent graft-versus-host disease in transplant recipients. However, clinicians often struggle with determining the most effective ATG dosing in HSCT because current protocols remain largely empirical. A recent study used Monte Carlo simulation to evaluate different regimens within a large in silico patient population of 10,000 adults. Researchers analyzed both conventional weight-based methods and novel individualized strategies to identify the best approach for patient care.

Interestingly, the results showed that conventional strategies achieved therapeutic targets in less than 25% of patients. The study defined the therapeutic target range as 60-95 AU·day/mL. Furthermore, regimens using total doses of 4-5 mg/kg provided the most consistent exposure among the tested groups. Despite these efforts, maintaining patients within the narrow therapeutic window proved difficult for every conventional regimen examined.

Challenges in Improving ATG dosing in HSCT

The investigation also examined dose optimization using empirical Bayesian estimation to refine individual pharmacokinetic parameters. Unfortunately, these advanced modeling techniques only increased target attainment by a slim 7% over baseline. Consequently, the researchers noted that Bayesian estimation performed poorly, with high shrinkage observed in several key parameters. This suggests that current model-informed precision dosing might not yet provide significant clinical advantages for transplant recipients.

Therefore, clinicians must continue to rely on standard weight-based protocols while research into pharmacokinetic variables continues. Identifying specific factors that influence ATG metabolism remains a priority for future studies. Until researchers can better predict individual patient responses, empirical dosing remains the most practical tool in the clinical setting.

Frequently Asked Questions

Why is weight-based dosing still the standard for ATG?

Weight-based dosing remains the standard because current pharmacodynamic models and precision dosing tools have not yet shown a significant enough clinical benefit to replace empirical methods.

What was the target range for ATG exposure in this study?

The study utilized a defined therapeutic target range of 60-95 AU·day/mL to evaluate the success of various dosing regimens.

Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or a professional relationship. Refer to the latest local and national guidelines for clinical practice.

References

Biris E et al. Evaluation of Current and Novel Dosing Strategies for Anti-Thymocyte Globulin in Adult Allogeneic Hematopoietic Stem Cell Transplantation. CPT Pharmacometrics Syst Pharmacol. 2026 May undefined. doi: 10.1002/psp4.70176. PMID: 42062785.

Wang H et al. Optimizing anti-thymocyte globulin dosing in allogeneic hematopoietic stem cell transplantation: individualized approaches and clinical implications. Front Immunol. 2025 Aug 8;16:1634157.

Ghazal H et al. Population Pharmacokinetics and Optimal Exposure of Antithymocyte Globulin in Myeloablative Hematopoietic Cell Transplantation. Transplant Cell Ther. 2026 Jan 12; PMID: 41534840.